Abstract:Breast cancer is still the most common cancer among women worldwide, causing a heavy burden of disease, mortality and long-term survival. In this context, women's participation in breast cancer research, especially in the leadership process, is important for increasing knowledge and developing health policy. However, gender gaps in leadership still exist. According to the 2023 OCSE report, women make up less than 30% of scientists worldwide, and their representation in senior positions and as decision-makers is even lower, especially in programs such as medical and experimental oncology. This under-representation not only hinders development of new ideas to solve complex diseases, such as breast cancer, but also impedes the progress needed to solve the specific health problems faced by women.Negative factors such as research funding bias, organizational bias, and lack of continuing education risk hindering women's advancement in scientific research. Furthermore, as a result of their significant contributions to research, female researchers should be recognized more for their contributions, leadership, and talent in relevant publications. The COVID-19 pandemic has further exacerbated inequality, negatively impacting female researchers who face greater supervisory responsibilities, thereby reducing research output. As we strive for a more social environment, it is even more important to provide platforms that support and promote the work of female scientists.The Frontiers in Oncology's Women in Breast Cancer series provides one such platform to share the diverse, valuable latest contributions of female researchers to breast cancer research. Volume III contains 21 articles covering a wide range of topics from molecular analysis and new diagnostics to clinical and patient care. These projects are all led by women and include a large number of female scientists, at various stages in their careers. Collectively, this series provides insight into the evolution of breast cancer research, providing a deeper understanding of early treatment and the biological, psychological, and treatment of the disease.Advances in breast cancer diagnostics are critical to improving early diagnosis and ensuring that patients receive the best possible treatment and personalized care. A key study in this volume investigates the ability of ultrasound-based radiography to estimate the expression of important markers such as oestrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 in breast cancer patients (Xu et al.). This new approach aims to eliminate molecular testing, reduces the need for biopsies, and offers a more efficient, patient-friendly alternative to traditional diagnostics. These advances are particularly important for improving diagnostic accuracy and guiding treatment in different types of breast cancer.This research is complemented by another study on breast calcification, which is often an early sign of malignancy. A new machine learning algorithm was developed to improve the segmentation and quantification of calcium in mammograms (Tong et al.). The algorithm is superior in identifying microcalcifications compared to existing models, improving the diagnostic process by helping radiologists distinguish malignant diseases. This AI-powered innovation holds great promise for improving early detection and reducing misdiagnosis, especially in difficult-to-find early-stage breast tissue.Advances in decisive oncology continue to improve breast cancer treatment. Much of the research in this issue focuses on personalized treatment strategies to improve outcomes based on the patient's molecular profile. A key example is the study of the Lem-D protein in triple-negative breast cancer (TNBC) (Rose et al.). Because TNBC lacks hormone receptors that are frequently targeted by other types of breast cancer, treatments are often limited. The researchers in this volume describe the role of nuclear envelope proteins, such as Ankle2, TMPO, and Emerin in TNBC cell growth, providing compelling evidence that these proteins may serve as a new treatment plan. This opens the door to more effective, targeted interventions for one of the most serious and difficult-to-treat breast cancers.Improving of personalized therapy also include traditional treatment such as radiotherapy. Comparative studies of conventional and hypofractionated radiation therapy using the Halcyon system highlight the importance of radiation therapy to stabilize the tumour with reduced side effects (Tai et al.). The hypofractionation approach, which delivers more radiation in fewer sessions, has been shown to be better minimizing side effects, even if not as effective in controlling tumours, as than conventional ones.Breast cancer, irrespective of its extent and treatment, has negative impacts on several aspects of women's lives. This issue includes several studies that highlight the importance of health-related qual -Abstract Truncated-

Large Publication Gap for Gynecologic Cancers in High–Impact Factor Journals

Comparison of publications between cancer sites in high impact factor journals.

Understanding disparities in research publications in high-impact factor journals by cancer site.

Abstract A005: Addressing Moonshot limitations: High-risk racial disparities in leading cancers

Abstract A090: Gender Disparities in the National Institutes of Health Funding for Breast Oncology

Disparities in National Cancer Institute and Nonprofit Organization Funding Disproportionately Affect Cancers With Higher Incidence Among Black Patients and Higher Mortality Rates

Gender disparities in the National Institutes of Health funding for gastrointestinal oncology.

Blueprint for cancer research: Critical gaps and opportunities

Editorial: Women in breast cancer, volume III: 2023

Turning the Tide Against Cancer Through Sustained Medical Innovation: The Pathway to Progress

Improving cervical cancer survival–A multifaceted strategy to sustain progress for this global problem

Gender imbalance in gynecologic oncology authorship and impact of COVID-19 pandemic

The high costs of anticancer therapies in the USA: challenges, opportunities and progress

Trends in Female Authorship in Major Journals of 3 Oncology Disciplines, 2002-2018

Gynecologic oncology top-cited articles: an international analysis

Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023

Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity

Navigating Precision Oncology: Insights from an Integrated Clinical Data and Biobank Repository Initiative across a Network Cancer Program

Fertility concerns in cancer patients: a bibliometric analysis via CiteSpace: A review

Disparities in availability of new cancer drugs worldwide: 1990-2022

Trends and hotspots in gastrointestinal neoplasms risk assessment: A bibliometric analysis from 1984 to 2022